A Phase 2 interventional study of Durvalumab and Methotrexate in Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors and Methotrexate, sponsored by AstraZeneca. Recruiting at 59 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing durvalumab in Urinary Bladder Neoplasms — 4 open to participants now, 12 under way, 3 of them phase 3. durvalumab · Urinary Bladder Neoplasms.
Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 17th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →4 of the 19 studies testing durvalumab in Urinary Bladder Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
Yuanquan Yang · Sites in United States
Ages 18+
AstraZeneca
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 3 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 39 across the 19 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Urinary Bladder Neoplasms by AstraZeneca: 5 open now, 11 under way, 4 of them phase 3. Of 9 finished, 2 (22%) have results posted.
Among the 20 studies in Urinary Bladder Neoplasms by AstraZeneca, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 16th registered.
AstraZeneca’s Urinary Bladder Neoplasms studies by the year they started, since 2003.
3 of the studies testing durvalumab in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03601455Jonsson Comprehensive Cancer CenterRadiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | 2027-01-31 |
| NCT03768570Canadian Cancer Trials GroupTrimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | 2027-03-31 |
| NCT06263153Yuanquan YangFutibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, from their registry updates:
Among AstraZeneca’s 20 in Urinary Bladder Neoplasms:
This tab as a report to print or save as PDF → With an account.
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
Not provided
The criteria were revised on the registry on Oct 8, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Durvalumab + chemotherapy, approximately 120 participants
Drug: Durvalumab · Drug: Methotrexate · Drug: Vinblastine · Drug: Doxorubicin · Drug: Cisplatin
Durvalumab + chemotherapy; approximately 30 participants; closed to further enrolment
Drug: Durvalumab · Drug: Gemcitabine · Drug: Cisplatin
Anti- PD-L1 Antibody.
Chemotherapy agent.
Chemotherapy agent
Chemotherapy agent
Chemotherapy agent
Anti- PD-L1 Antibody (discontinued to further enrollment)
Chemotherapy agent (discontinued to further enrollment)
Chemotherapy agent (discontinued to further enrollment)
The safety of neoadjuvant durvalumab combined with ddMVAC prior to radical cystectomy (RC).
Incidence of Grade 3 or 4 possibly treatment-related adverse events observed from the first dose of neoadjuvant study treatment until RC or the corresponding prespecified endpoint-window end date for participants who do not undergo RC
Time frame: Up to 6 months
The safety and tolerability of perioperative durvalumab combined with neoadjuvant therapy
Incidence, severity, nature, seriousness, outcome and causality of treatment-emergent adverse events, including PRAEs, adverse events of special interest, immune-mediated adverse events and serious adverse events; adverse events leading to study treatment interruption or discontinuation; and clinically relevant laboratory abnormalities
Time frame: Up to 2 years
The efficacy of perioperative durvalumab combined with ddMVAC in terms of event-free survival (EFS).
EFS is defined as the time from first neoadjuvant durvalumab + chemotherapy treatment until the earliest occurrence of any of the following events: * First recurrence of disease after RC * First documented progression in participants who were medically precluded from RC * Time of expected surgery in participants who refuse to undergo RC or failure to undergo RC in participants with residual disease * Death due to any cause. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.
Time frame: Up to 3 years
The efficacy of perioperative durvalumab combined with ddMVAC in terms of disease-free survival (DFS).
DFS is defined as the time from the date of RC to the earliest of the first recurrence of disease post RC or death due to any cause. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.
Time frame: Up to 3 years
The efficacy of perioperative durvalumab combined with ddMVAC in terms of OS.
OS is defined as the time from first neoadjuvant durvalumab + chemotherapy until death due to any cause. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.
Time frame: Up to 3 years
The efficacy of neoadjuvant durvalumab combined with ddMVAC followed by RC in terms of pathological complete response (pCR).
pCR rate is defined as the proportion of participants whose pathologic staging is T0N0M0 as assessed per local pathology review using specimens obtained via RC. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.
Time frame: Up to 3 years
The efficacy of neoadjuvant durvalumab combined with ddMVAC followed by RC in terms of pathologic downstaging (pDS).
pDS rate is defined as the proportion of participants whose pathologic staging is \<P2 per local pathology review using specimens obtained via RC. Data from the legacy Gem/Cis cohort will be summarized for completeness, where applicable.
Time frame: Up to 3 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Aug 2028, 39 months after the start.
Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 39 months is close to that.
Counting every sponsor, half of 194 studies reached it within 52 months; a quarter within 36 and three quarters within 91.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Oct 2028 → Aug 2028 and completion Oct 2028 → Aug 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab